Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Epigral Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,344.65Undervalued by 11.77%vs CMP ₹1,203.00

P/E (15.4) × ROE (22.3%) × BV (₹487.00) × DY (0.50%)

₹1,012.94Overvalued by 15.80%vs CMP ₹1,203.00
MoS: -18.8% (Negative)Confidence: 58/100 (Moderate)Models: 2 Under, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,414.1422%Under (+17.6%)
Graham NumberEarnings₹926.0916%Over (-23%)
Earnings PowerEarnings₹508.2211%Over (-57.8%)
DCFCash Flow₹944.8113%Over (-21.5%)
Net Asset ValueAssets₹486.867%Over (-59.5%)
EV/EBITDAEnterprise₹1,832.209%Under (+52.3%)
Earnings YieldEarnings₹782.707%Over (-34.9%)
ROCE CapitalReturns₹912.959%Over (-24.1%)
Revenue MultipleRevenue₹591.185%Over (-50.9%)
Consensus (9 models)₹1,012.94100%Overvalued

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 5.2%

*Investments are subject to market risks

Analyst Summary

Epigral Ltd operates in the Agro Chemicals/Pesticides segment, NSE: EPIGRAL | BSE: 543332, current market price is ₹1,203.00, market cap is 5,189 Cr.. At a glance, stock P/E is 15.4, ROE is 22.3 %, ROCE is 24.9 %, book value is 487, dividend yield is 0.50 %. The latest intrinsic value estimate is ₹1,012.94, around 15.8% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹2,550 Cr versus the prior period change of 32.2%, while latest net profit is about ₹357 Cr with a prior-period change of 82.1%. The 52-week range shown on this page is 2,114/806, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisEpigral Ltd. is a Public Limited Listed company incorporated on 11/09/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2007P…

This summary is generated from the stock page data available for Epigral Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

57
Epigral Ltd scores 57/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health79/100 · Strong
ROCE 24.9% ExcellentROE 22.3% ExcellentD/E 0.87 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 68.8% Stable
Earnings Quality40/100 · Moderate
OPM contracting (32% → 27%) Declining
Quarterly Momentum30/100 · Weak
Revenue (4Q): -1% YoY FlatProfit (4Q): -3% YoY DecliningOPM: 17.0% (down 11.0% YoY) Margin pressure
Industry Rank80/100 · Strong
P/E 15.4 vs industry 29.2 Cheaper than peersROCE 24.9% vs industry 15.3% Above peers3Y sales CAGR: 18% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 26, 2026, 1:28 am

Market Cap 5,189 Cr.
Current Price 1,203
Intrinsic Value₹1,012.94
High / Low 2,114/806
Stock P/E15.4
Book Value 487
Dividend Yield0.50 %
ROCE24.9 %
ROE22.3 %
Face Value 10.0
PEG Ratio2.98

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Epigral Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Epigral Ltd 5,189 Cr. 1,203 2,114/80615.4 4870.50 %24.9 %22.3 % 10.0
Rallis India Ltd 4,988 Cr. 256 386/21627.1 1060.97 %10.1 %6.65 % 1.00
Dhanuka Agritech Ltd 4,788 Cr. 1,062 1,975/89016.4 3110.19 %28.3 %22.0 % 2.00
NACL Industries Ltd 3,611 Cr. 154 311/113 19.00.00 %7.80 %25.8 % 1.00
Bhagiradha Chemicals & Industries Ltd 3,362 Cr. 259 331/170139 54.90.06 %7.44 %4.91 % 1.00
Industry Average10,334.70 Cr1,093.4529.21373.290.48%15.30%19.97%6.67

All Competitor Stocks of Epigral Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 538562455478472525651626645628607587597
Expenses 371407360370349369475448463454443455494
Operating Profit 16715595108123155176178183173163132103
OPM % 31%28%21%23%26%30%27%28%28%28%27%23%17%
Other Income -0521222643826
Interest 2119182120141427-012232211
Depreciation 31303132313033323334424243
Profit before tax 1141104856741131311241541311077055
Tax % 33%30%33%32%34%32%34%35%33%34%-50%26%28%
Net Profit 7777323849778681104871605239
EPS in Rs 18.5818.487.629.1811.8718.4520.7019.3824.0020.0837.1811.949.07

Last Updated: February 2, 2026, 2:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 4:55 am

MetricMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3943925987106118291,5512,1881,9292,5502,419
Expenses 2452483464054165671,0411,4991,4481,8391,847
Operating Profit 149144252306194261510689481711572
OPM % 38%37%42%43%32%32%33%31%25%28%24%
Other Income 21816224861519
Interest 191492511294466735368
Depreciation 44555554447486109124133161
Profit before tax 8875195242141161383523291540362
Tax % 23%11%20%25%21%37%34%32%33%34%
Net Profit 6767155183112101253353196357338
EPS in Rs 9.499.4021.9744.3827.1924.4860.8485.0447.1282.6878.27
Dividend Payout % 0%0%0%0%0%0%0%6%11%7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%131.34%18.06%-38.80%-9.82%150.50%39.53%-44.48%82.14%
Change in YoY Net Profit Growth (%)0.00%131.34%-113.28%-56.86%28.98%160.32%-110.97%-84.00%126.62%

Epigral Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:33%
3 Years:18%
TTM:18%
Compounded Profit Growth
10 Years:%
5 Years:26%
3 Years:12%
TTM:72%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:7%
1 Year:-5%
Return on Equity
10 Years:%
5 Years:27%
3 Years:25%
Last Year:22%

Last Updated: September 5, 2025, 3:26 pm

Balance Sheet

Last Updated: March 3, 2026, 2:55 am

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 7171714142424242424343
Reserves 2242914472413314326841,0281,2131,8602,057
Borrowings 19012374601737753993879964593537
Other Liabilities 554279162164223405484576655598
Total Liabilities 5405276711,0441,2731,4492,1242,4322,7943,1513,235
Fixed Assets 3643983472954401,1021,0681,8041,7672,2382,176
CWIP 6937946869112658915848364309
Investments 02971000021219744
Other Assets 10698173281142221467449524752707
Total Assets 5405276711,0441,2731,4492,1242,4322,7943,1513,235

Reserves and Borrowings Chart

Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 165229284626398441
Cash from Investing Activity + -363-197-455-437-401-262
Cash from Financing Activity + 69-32195-200-8-164
Net Cash Flow -129124-11-1115
Free Cash Flow -20532-172210-1254
CFO/OP 99%99%68%106%93%78%

Free Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-41.0021.00178.00-295.00-543.00-492.00-483.00-190.00-483.00118.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 43414740465260283433
Inventory Days 755945586451746990105
Days Payable 31375152626942366350
Cash Conversion Cycle 86634246483492616188
Working Capital Days 434019-27-76-92-26-41-5426
ROCE %18%37%36%15%16%29%32%17%25%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 71.34%71.37%71.38%71.38%71.49%71.58%71.58%68.94%68.95%68.83%68.83%68.83%
FIIs 1.20%1.16%1.14%1.17%1.36%1.46%2.10%3.01%3.01%3.06%2.71%2.36%
DIIs 0.03%0.04%0.04%0.05%0.02%0.18%1.17%4.31%4.66%4.78%4.93%5.13%
Government 0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%
Public 27.39%27.39%27.40%27.37%27.10%26.75%25.12%23.71%23.34%23.30%23.52%23.67%
No. of Shareholders 94,77895,83395,74292,95988,87085,76183,17681,69780,87879,95178,60577,562

Shareholding Pattern Chart

No. of Shareholders

Epigral Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Bandhan Small Cap Fund 886,448 0.39 79.05865,4482026-03-24 02:05:082.43%
HSBC Value Fund 494,874 0.3 44.13N/AN/AN/A
HSBC Focused Fund 250,650 1.32 22.35N/AN/AN/A
HSBC ELSS Tax saver Fund 121,645 0.27 10.85N/AN/AN/A
HSBC Business Cycles Fund 76,350 0.62 6.81N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 84.6847.1485.0360.8424.27
Diluted EPS (Rs.) 84.6847.1485.0360.8424.27
Cash EPS (Rs.) 113.4176.87111.2581.5141.97
Book Value[Excl.RevalReserv]/Share (Rs.) 441.48301.83257.30174.72113.88
Book Value[Incl.RevalReserv]/Share (Rs.) 441.48301.83257.30174.72113.88
Revenue From Operations / Share (Rs.) 591.13464.30526.69373.27199.41
PBDIT / Share (Rs.) 168.27117.39167.73123.6163.42
PBIT / Share (Rs.) 137.5487.66141.51102.9345.72
PBT / Share (Rs.) 125.2069.97125.7592.2838.71
Net Profit / Share (Rs.) 82.6847.1385.0360.8424.27
NP After MI And SOA / Share (Rs.) 82.9147.1485.0360.8424.27
PBDIT Margin (%) 28.4625.2831.8433.1131.80
PBIT Margin (%) 23.2618.8726.8627.5722.92
PBT Margin (%) 21.1715.0623.8724.7219.41
Net Profit Margin (%) 13.9810.1516.1416.2912.16
NP After MI And SOA Margin (%) 14.0210.1516.1416.2912.16
Return on Networth / Equity (%) 18.7815.6133.0434.8221.30
Return on Capital Employeed (%) 22.3018.0732.9426.8717.92
Return On Assets (%) 11.347.0014.5211.906.96
Long Term Debt / Equity (X) 0.230.390.401.060.71
Total Debt / Equity (X) 0.300.720.711.360.87
Asset Turnover Ratio (%) 0.850.730.960.860.00
Current Ratio (X) 1.570.640.640.830.46
Quick Ratio (X) 0.780.300.320.550.32
Inventory Turnover Ratio (X) 7.834.516.627.300.00
Dividend Payout Ratio (NP) (%) 8.825.302.940.000.00
Dividend Payout Ratio (CP) (%) 6.433.252.240.000.00
Earning Retention Ratio (%) 91.1894.7097.060.000.00
Cash Earning Retention Ratio (%) 93.5796.7597.760.000.00
Interest Coverage Ratio (X) 13.636.6410.6411.609.05
Interest Coverage Ratio (Post Tax) (X) 7.703.666.396.714.46
Enterprise Value (Cr.) 8753.815509.594780.475010.230.00
EV / Net Operating Revenue (X) 3.432.862.183.230.00
EV / EBITDA (X) 12.0611.306.869.760.00
MarketCap / Net Operating Revenue (X) 3.212.361.792.610.00
Retention Ratios (%) 91.1794.6997.050.000.00
Price / BV (X) 4.303.633.675.570.00
Price / Net Operating Revenue (X) 3.212.361.792.610.00
EarningsYield 0.040.040.090.060.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Epigral Ltd. is a Public Limited Listed company incorporated on 11/09/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2007PLC051717 and registration number is 051717. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 2550.13 Cr. and Equity Capital is Rs. 43.14 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Agro Chemicals/Pesticides�Epigral Tower�, Behind Safal Profitaire, Ahmedabad Gujarat 380015Contact not found
Management
NamePosition Held
Mr. Maulik PatelChairman & Managing Director
Mr. Kaushal SoparkarExecutive Director
Mr. Ankit PatelNon Exe.Non Ind.Director
Mr. Karana PatelNon Exe.Non Ind.Director
Mr. Darshan PatelNon Exe.Non Ind.Director
Mr. Manubhai PatelIndependent Director
Mr. Sanjay AsherIndependent Director
Mr. Kanubhai PatelIndependent Director
Mr. Raju SwamyIndependent Director
Ms. Priyanka ChopraIndependent Woman Director

FAQ

What is the intrinsic value of Epigral Ltd and is it undervalued?

As of 28 April 2026, Epigral Ltd's intrinsic value is ₹1012.94, which is 15.80% lower than the current market price of ₹1,203.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (22.3 %), book value (₹487), dividend yield (0.50 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Epigral Ltd?

Epigral Ltd is trading at ₹1,203.00 as of 28 April 2026, with a FY2026-2027 high of ₹2,114 and low of ₹806. The stock is currently in the middle of its 52-week range. Market cap stands at ₹5,189 Cr..

How does Epigral Ltd's P/E ratio compare to its industry?

Epigral Ltd has a P/E ratio of 15.4, which is below the industry average of 29.21. This is broadly in line with or below the industry average.

Is Epigral Ltd financially healthy?

Key indicators for Epigral Ltd: ROCE of 24.9 % indicates efficient capital utilization; ROE of 22.3 % shows strong shareholder returns. Dividend yield is 0.50 %.

Is Epigral Ltd profitable and how is the profit trend?

Epigral Ltd reported a net profit of ₹357 Cr in Mar 2025 on revenue of ₹2,550 Cr. Compared to ₹253 Cr in Mar 2022, the net profit shows an improving trend.

Does Epigral Ltd pay dividends?

Epigral Ltd has a dividend yield of 0.50 % at the current price of ₹1,203.00. The company pays dividends, though the yield is modest.

Last Updated: April 26, 2026, 1:28 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543332 | NSE: EPIGRAL
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Epigral Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports